Key Insights• The Argentina biosurgery market represents the second-largest national market for surgical biomaterials in South America and a key entry point for manufacturers targeting the Southern Cone region. Valued at more than USD 98 million in 2025, the market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The Argentina biosurgery market is distinguished by its universal healthcare system, a well-developed private healthcare sector (prepagas), and significant surgical volumes across orthopedic, general, and cardiovascular specialties. According to the World Bank, Argentina's health spending reached 10.36% of GDP in 2025 (ranking 26th globally), having risen steadily from 8.22% of GDP in 2000. Health expenditure per capita stood at approximately $1,756 in 2025. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models, including the growing adoption of minimally invasive surgical techniques and the rapid expansion of medical device imports.• The Argentina biosurgery market was valued at more than USD 98 million in 2025, making it the second-largest biosurgery market in South America. Health spending reached 10.36% of GDP (ranking 26th globally), providing a substantial financial foundation for surgical activity.

Bone-Graft Substitutes represent the largest product category within the Argentine biosurgery market, driven by the high volume of orthopedic and trauma procedures. Argentina's rapidly aging population with 12.6% aged 65 and older in 2025 (5.79 million people) continues to drive demand for musculoskeletal interventions.• Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive surgical techniques and the growing volume of laparoscopic and endoscopic procedures across Argentine hospitals.Argentina's aging population represents a significant long-term demand driver. The population aged 65 and older has increased from 5.67 million in 2024 to 5.79 million in 2025, a 2.1% year-over-year growth. Life expectancy reached 80 years for females and 75 years for males in 2025.• The regulatory environment, centered on ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica), is undergoing significant modernization. In 2025-2026, ANMAT introduced several major reforms including Provision 64/2025 for updated registration requirements and Disposition 8799/2025 for simplified approval of Class I/II medical devices.Market Outlook• According to the research report, " Argentina Biosurgery Market Overview, 2031 Overview, 2031," published by Actual Market Research, the Argentina Biosurgery market was valued at more than USD 98 Million in 2025.• The Argentine biosurgery market is expected to maintain steady growth through 2031, supported by favorable demographic trends, ongoing technological innovation, expanding surgical volumes, and regulatory modernization. The market's growth trajectory is intrinsically linked to the broader Argentine healthcare landscape, including healthcare expenditure, technological adoption, and demographic shifts.• The aging Argentine population represents the most significant long-term demand driver.

As of 2025, 12.6% of the population (approximately 5.79 million people) was aged 65 years or older. The population aged 65 and above has grown from 4.49 million in 2012 to 5.79 million in 2025, representing a 29% increase over 13 years. Life expectancy reached record highs of 80 years for women and 75 years for men in 2025. The median age has surpassed 32 years, confirming the trend toward an increasingly adult and aging population.• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. Argentina is witnessing a rapid shift toward minimally invasive surgical techniques. The country is a founding member of Mercosur (alongside Brazil, Paraguay, Uruguay, and Bolivia), meaning regulatory work done for Argentina can be leveraged across the bloc.• Rising surgical procedures and expanding healthcare access are key drivers propelling market expansion.

Argentina performs hundreds of thousands of surgical procedures annually across its extensive network of public and private hospitals. The country has established itself as a destination for medical tourism, with more than 28,000 annual aesthetic interventions. Organ transplantation procedures have doubled since 2003, positioning Argentina among the countries with the highest development in organ procurement.Market DynamicsDriver: High Surgical Volumes and Aging PopulationArgentina performs hundreds of thousands of surgical procedures annually across its extensive network of public and private hospitals. The country has established itself as a destination for medical tourism, with more than 28,000 annual aesthetic interventions. Organ transplantation procedures have doubled since 2003, positioning Argentina among the countries with the highest development in organ procurement. The aging population with 12.6% aged 65 and older and 5.79 million people in this demographic continues to drive demand for musculoskeletal, cardiovascular, and ophthalmic interventions.

Health spending of 10.36% of GDP provides substantial financial resources to support expanding surgical volumes. The continued expansion of surgical capacity, driven by hospital modernization and the growing network of healthcare facilities, further reinforces this demand driver.Challenge: Healthcare Infrastructure Constraints and Economic VolatilityDespite the market's growth potential, Argentina faces significant challenges that affect the biosurgery market. Hospital bed density in Argentina stands at 2.95 beds per 1,000 population in 2025, ranking 55th globally and representing a 12.2% decrease from 2024. This marks a substantial drop from the country's all-time peak of 6.35 beds per 1,000 people in 1960. The downward trend suggests that Argentina's healthcare infrastructure has struggled to keep pace with its growing population. Additionally, the healthcare system faces pressures from economic volatility and inflationary pressures, which have impacted health spending from an all-time peak of 11.01% of GDP in 2021 to 10.36% in 2025.

Approximately 10.3 million people (over 22% of the population) depend solely on the public healthcare system, with 742,000 people having lost private coverage in 2025. These constraints create pricing pressure on biosurgical products and may limit adoption of premium-priced advanced biologics.Trend: Accelerating Regulatory Modernization and Medical Device ImportsThe Argentine biosurgery market is experiencing significant transformation driven by regulatory modernization and increasing medical device imports. The Argentina biosurgery market witnessed a steady increase in imports from 2020 to 2024, with a Compound Annual Growth Rate (CAGR) of 3.65%. ANMAT has introduced several significant reforms in 2025-2026, including Provision 64/2025 for updated registration requirements and Disposition 8799/2025, which allows businesses involved in the production and importation of Class I and II medical devices to opt for a simplified procedure to gain national health authorization. ANMAT has also implemented reliance mechanisms for the authorization of low-risk medical device manufacturing or importing establishments and developed digital platforms such as the ARGOS system. Additionally, ANMAT Regulation 2857/2025 allows the importation for personal use of non-prescription medical devices.

This regulatory modernization is facilitating faster market access for innovative biosurgical products.Policies• ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) serves as Argentina's national regulatory authority for health products, functionally equivalent to the US FDA. ANMAT is an observer member of the International Medical Device Regulators Forum (IMDRF).• Provision 64/2025 establishes updated registration requirements for medical products, reflecting ANMAT's ongoing regulatory modernization.• Disposition 8799/2025 allows businesses involved in the production and importation of Class I and II medical devices to opt for a simplified procedure to gain national health authorization.• ANMAT Regulation 2857/2025 allows the importation for personal use of non-prescription medical devices, simplifying access for individual patients.• ANMAT Regulation 2565/2025 establishes that imported medical devices may not enter the country if their expiration date is less than six months, ensuring quality standards.• Argentina's Mercosur membership (alongside Brazil, Paraguay, Uruguay, and Bolivia) means regulatory work done for Argentina can be leveraged across the bloc.Segment AnalysisArgentina Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the Argentine biosurgery market, driven by the high volume of orthopedic and trauma procedures. Argentina's aging population with 12.6% aged 65 and older continues to drive demand for musculoskeletal interventions. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors, widely utilized in trauma fixation, spinal fusion, and joint replacement procedures.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. The Argentina biosurgery market witnessed a steady increase in imports from 2020 to 2024, with a CAGR of 3.65%, reflecting growing demand.• Surgical Sealants and Adhesives represent the fastest-growing product category in the Argentine biosurgery market, driven by increasing adoption of minimally invasive surgical techniques.

These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The growing volume of laparoscopic and endoscopic procedures across Argentine hospitals supports the expansion of this segment.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures. Argentine companies such as InBiomed design, develop, and produce biomaterials used for bone and soft tissue reconstructions in dentistry, plastic surgery, traumatology, and neurosurgery.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.Argentina Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in Argentina, driven by the high volume of trauma surgeries, joint replacements, and spinal procedures.

Argentina's aging population with 12.6% aged 65 and older continues to drive demand for musculoskeletal interventions. Argentine companies such as Human Balance Cirugía import and distribute medical products, instruments, equipment, and implants for traumatological surgery.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers.• Cardiovascular Surgery represents the fastest-growing application area in the Argentine biosurgery market, driven by the high prevalence of cardiovascular disease and the aging population. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery. Argentina has established itself as a destination for medical tourism, with more than 28,000 annual aesthetic interventions.

A total of 209,760 plastic surgeries were performed, including 4,013 intimate procedures.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.Argentina Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the Argentine biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. ANMAT's rigorous requirements for biological materials ensure high safety standards.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Argentine market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The Argentine healthcare system's emphasis on cost-effectiveness and the growing domestic manufacturing sector favor synthetic alternatives for certain applications.Argentina Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in Argentina, accounting for the majority of revenue. Argentina has 3,951 health establishments with hospitalization and 25,808 without hospitalization.

Public hospitals under the national, provincial, and municipal systems perform the majority of surgical procedures. Over 80% of the population accesses healthcare through the public system or prepagas.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Argentine biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity supports the adoption of biosurgical products in these settings.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.Market Overview, 2031 Outlook by Healthcare Spending and Infrastructure• Argentine Biosurgery market growth is strongly linked to livestock sector development, pet healthcare expenditure, and veterinary infrastructure modernization. With a bovine herd of 50.92 million cattle and 80% of households owning pets, the addressable market remains substantial. The livestock sector, though experiencing herd contraction, remains critical to export revenues, driving demand for disease surveillance and food safety testing. The pet sector's exceptional growth, driven by cultural transformation and the humanization of companion animals, is expanding the commercial reference laboratory market.• Veterinary healthcare infrastructure continues to develop across Argentina.

SENASA maintains the National Laboratory in Martínez and the National Laboratory Network including regional and private registered laboratories. The laboratory registration framework under Resolution 1446/2024 ensures quality and biosafety standards. The unified accreditation framework established by Resolution 43/2026 creates a streamlined process for private veterinarians to participate in official surveillance activities, expanding the reach of diagnostic services. The SIGVET system provides traceability for veterinary product trade.• Private healthcare expenditure plays an increasingly important role, especially for advanced diagnostic testing and specialty veterinary care. Private veterinary hospitals and specialty referral centers in metropolitan regions are expanding diagnostic capabilities. Corporate veterinary hospital groups and specialty veterinary clinics are consolidating reference laboratory purchasing decisions and driving demand for standardized diagnostic services.

The high pet ownership rate and increased willingness to invest in pet healthcare are expanding the commercial reference laboratory market.• Public healthcare investment remains foundational to the market's growth. SENASA provides diagnostic services through its National Laboratory and network, with fee-for-service pricing established under tariff resolutions. The National Epidemiological Surveillance System maintains mandatory disease notification and surveillance activities. International cooperation with WOAH supports diagnostic capacity development and maintenance of disease-free status. The World Organisation for Animal Health recognizes Argentina's disease-free status for various diseases based on annual surveillance data submission.• The future growth opportunity for veterinary reference laboratories in Argentina depends on improving access to specialized diagnostic services, expanding the network of registered laboratories, increasing adoption of molecular diagnostics, strengthening One Health surveillance systems, and continuing to advance diagnostic technologies. The Argentine government's strategic emphasis on animal health security, food safety, and international trade provides a favorable policy environment for continued market growth.

The Servicio Nacional de Sanidad y Calidad Agroalimentaria (SENASA), the National Laboratory Network, and the registered private laboratories remain critical to protecting Argentine animal health, public health, and the security of the food supply.Argentina Biosurgery Market Economics• Argentina’s biosurgery market operates through a mixed healthcare system comprising public healthcare, private insurance (prepagas), and social security (obras sociales). Healthcare expenditure reached approximately 10.36% of GDP in 2025, with per-capita spending of about USD 1,756. Around 10.3 million people rely solely on public healthcare, while economic volatility and inflation create pricing and reimbursement pressures. Manufacturers must navigate public tenders, private procurement, and growing medical device imports.• Argentina has a broad healthcare infrastructure, with 3,951 establishments providing hospitalization and 25,808 without hospitalization. However, hospital bed density declined to 2.95 beds per 1,000 population in 2025, highlighting infrastructure constraints. The country has approximately 5.23 physicians per 1,000 population, supporting surgical capacity despite workforce distribution challenges.

Its membership in Mercosur also provides manufacturers with opportunities to leverage regulatory and commercial capabilities across Brazil, Paraguay, Uruguay, and Bolivia.• Domestic manufacturing and innovation are increasingly important to the market. Companies such as InBiomed, Sirex Bios, and Human Balance Cirugía are developing biomaterials, implants, fillers, and customized 3D-printed surgical products. ANMAT is modernizing the regulatory environment through simplified approval pathways, reliance mechanisms, and digital platforms such as ARGOS. These developments are improving market access while supporting investment in advanced biomaterials, minimally invasive procedures, and customized surgical technologies.• Argentina’s long-term biosurgery outlook remains positive despite economic challenges. The country has approximately 45.9 million people, with 5.79 million aged 65 or older, representing 12.6% of the population. The biosurgery market was valued at more than USD 98 million in 2025, following a 3.65% CAGR during 2020–2024.

Regulatory modernization, ageing demographics, increasing technology adoption, and domestic manufacturing will support future growth, although inflation and procurement pressures remain key challenges.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.